Close menu




June 14th, 2022 | 12:26 CEST

Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold

  • Biotechnology
  • travel
  • Gold
  • Mining
Photo credits: pixabay.com

There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , LUFTHANSA AG VNA O.N. | DE0008232125 , TRIUMPH GOLD CORP. | CA8968121043

Table of contents:


    BioNTech: Is BA.5 getting ahead of the vaccines?

    BioNTech's stock has lost about 7% of its value in recent trading days. However, if one takes a long-term view of the share, it has stabilized at around EUR 150 for several months. In this area, the value could have found a bottom. Such a consolidation can be interpreted in two ways: First, there is no selling pressure to push the stock lower, but second, there is also no need to pay higher prices for a share, as the supply of around EUR 150 still exceeds the demand. Nevertheless, since the consolidation has been going on for months now, investors should not wait too long before analyzing BioNTech. Those toying with the idea of a purchase should do the groundwork now.

    A key driver of the stock's outlook could be the adapted vaccines scheduled to begin shipping in the fall. Even an additional variant, which is both contagious and dangerous, is not yet off the table. Regarding BA.5, however, it looks as if natural immunity will win the race against the vaccine manufacturers. The vaccination pressure may drop for many people who have just been through an infection. However, investors should keep in mind with BioNTech that the biotech company has more to offer than vaccines against Corona. Investors should keep the stock in mind just in case.

    Lufthansa: Travel lust turns into travel frustration

    From an investor's perspective, a counter to BioNTech could be the Lufthansa share. Why? The airline is just benefiting from the easing a few months ago. Many people are rushing to get outside. The mood at airports is relaxed. However, the increasing problems due to Corona are causing tensions as more and more flights are cancelled, ground staff are in short supply, and long queues are forming at the security check. Given the prospects surrounding BA.5 - in Portugal, one in two people are infected - the desire to travel could be dampened. Lufthansa's share price, which in any case has no upper hand at the moment, also remains unattractive.

    Triumph Gold: Will 2020 be a repeat? Warning signals ahead!

    Triumph Gold, a gold stock operating in the Canadian Yukon, also makes an unattractive impression at first glance. The share has been running sideways for about a year. Recently, the price stabilized a little. Triumph Gold is a typical gold prospector: Still, far from production, perspective and fantasy rule the share price. Where this can lead is shown by the development between March and July 2020 - within this time, Triumph's price had more than doubled. What happened then?

    First, the pandemic depressed prices, and then governments around the world reacted and pumped capital into the economy. This obvious imbalance pushed up the gold price and, in the next step, shares of Triumph Gold. Currently, there are signs of turmoil in the markets again. Inflation remains high - it recently reached another forty-year high in the USA. At the same time, bonds are making movements that only occur during crises. Ten-year government bonds from Germany are now yielding 1.5% - just a few weeks ago, the yield was 0.3%. Although growth companies are currently still suffering from the overall environment, the wheat could soon be separated from the chaff, as was already the case in 2020. Gold stocks are often in demand during crises, and investors should note promising stocks such as Triumph Gold, in which Newmont and Teck Resources, among others, are major shareholders.


    Travel lust or travel frustration? Pandemic profiteer or non-starter? If you cannot decide between stocks like Lufthansa and TUI on the one hand, and BioNTech and Valneva on the other, you might want to think about gold. While cryptocurrencies continue to fall, the millennial surrogate currency is holding steady. Small stocks like Triumph Gold can provide leverage on gold prices during rally phases.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

    Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

    • Biotechnology

    Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

    Read

    Commented by Stefan Feulner on June 30th, 2022 | 11:03 CEST

    Tocvan Ventures and BYD with outstanding news - TeamViewer plunges into a bottomless pit

    • Gold
    • Silver
    • Technology
    • Battery

    The current correction has hit interest-sensitive growth stocks particularly hard. The US technology exchange NASDAQ, for example, has lost around 34% of its value since the beginning of the year and its high of 16,670 points. Investors did not even stop at shares in future technologies such as electromobility. But in contrast to top dog Tesla - Musk's shares have halved in value within six months - Chinese competitor BYD is rushing from one high to the next. There is also strong news from a promising gold and silver exploration company. A gold price that experts expect to be positive in the long term could help the company to outperform.

    Read

    Commented by Stefan Feulner on June 30th, 2022 | 10:09 CEST

    Rheinmetall on the verge of a breakout, and MAS Gold and K+S with rebound opportunity

    • Defense
    • Gold
    • fertilizer

    Due to the uncertain geopolitical situation regarding the Ukraine conflict and concerns about inflation getting out of hand, the most important stock market indices are again turning downward. Germany's leading index, the DAX, is once again struggling with the psychologically important 13,000-point mark. With the exception of defense stocks, there is downward pressure across the board. Fertilizer manufacturers, which initially benefited particularly from the sanctions against Russia, are also correcting sharply and offering interesting entry opportunities for long-term investors. The precious metals markets are also running into attractive buying zones.

    Read